

PATIENT INFORMATION

| | | |
|--|--|-----------------------------|
| First name | MI | Last name |
| Date of birth (MM/DD/YYYY) | Sex <input type="radio"/> M <input type="radio"/> F | MRN (medical record number) |
| Ancestry <input type="radio"/> Asian <input type="radio"/> Black/African American <input type="radio"/> White/Caucasian <input type="radio"/> Ashkenazi Jewish <input type="radio"/> Hispanic <input type="radio"/> Native American <input type="radio"/> Pacific Islander <input type="radio"/> Other: | | |
| ▶ Email address (for report access after release by medical professional) | | |
| Phone | Is this patient deceased? <input type="radio"/> Yes <input type="radio"/> No Deceased date: | |
| Address | | City |
| State | ZIP code | Country |

SPECIMEN INFORMATION

Label each tube with the patient's full name, date of birth, and specimen collection date. A requisition form MUST accompany each specimen. www.invitae.com/specimen-requirements

Specimen type: Blood Saliva Assisted saliva DNA - source:
DNA must be extracted in a CLIA or other suitably certified laboratory
We are unable to accept blood/saliva from patients with:

- Allogeneic bone marrow transplants
- Blood transfusion <2 weeks prior to specimen collection

| | |
|--------------------------------|--|
| ▶ Collection date (MM/DD/YYYY) | Special cases <input type="radio"/> History of/current hematologic malignancy <input type="radio"/> Resubmission |
|--------------------------------|--|

REASON FOR TESTING

Primary indication: Hereditary breast and ovarian cancer (HBOC)
 Lynch Syndrome
 Polyposis (FAP)
 Other: _____

| | |
|--------------|------------------|
| ICD-10 codes | Previous results |
|--------------|------------------|

Testing for a personal history of disease? Yes No If yes, describe below.
Age at diagnosis: _____

ORGANIZATION INFORMATION

Organization name and address

Organization name

Phone Fax

Address City

State ZIP code Country

Primary clinical contact

Name Role/title

Phone NPI

Email address (for report access)

Ordering physician

Same as primary clinical contact

Name NPI

Email address (for report access)

Additional clinical or laboratory contact (optional)

Name Email address (for report access)

Letter of Medical Necessity (LMN)

I have attached an LMN and/or other documentation for insurance billing purposes.
 I agree to allow Invitae to transfer the information from this requisition to an LMN and/or other documentation using the ordering physician's name as the signature for insurance billing.

Family history? Yes No If yes, describe in detail below or attach pedigree. If there is a known familial variant, indicate here.

INSURANCE BILLING (U.S. ONLY)

I have attached a copy of the patient's card

| | |
|--|-----------------------|
| Insurance company name | Member ID# |
| Patient relation to policy holder: <input type="radio"/> Self <input type="radio"/> Child <input type="radio"/> Spouse <input type="radio"/> Other | |
| Policy holder name | Prior-authorization # |

PATIENT PAY BILLING

Invitae will send an electronic invoice to the patient email listed above

INSTITUTIONAL BILLING

Send invoice to organization address above

| | | |
|-----------------------|----------|---------|
| Billing contact name | Phone | Fax |
| Billing email address | | |
| Billing address | | City |
| State | ZIP code | Country |

OTHER BILLING Invitae partner code:

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing (www.invitae.com/patient-consent), and has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated). The Patient has further been informed and hereby authorizes Invitae Corporation ("Invitae") and its designees to release information concerning testing to their insurer in order to process and/or appeal claims on behalf of the Patient. For amounts received directly, the Patient agrees to remit payment to Invitae for testing services rendered. I acknowledge that I offered pre-test Genetic Counseling to the Patient, if required by their insurer. In addition to the above, I attest that I am the ordering physician, or I am authorized by the ordering physician to order this test, or I am authorized under applicable state law to order this test.

| | |
|----------------------------------|------|
| ▶ Medical professional signature | Date |
|----------------------------------|------|

ORDER INSTRUCTIONS: Select a pre-curated test, combine multiple tests, or customize your own test for each patient. Invitae's pricing is per clinical area for initial order and re-requisition. All tests on this form fall into a single clinical area. If your order contains tests from multiple clinical areas, you will need to send in two sample tubes and your order will represent two billable events. Your test results will be delivered as two reports. Please contact Client Services with any questions. For Invitae's full test menu, please visit www.invitae.com.

RE-REQUISITION: Invitae offers one re-requisition at no additional charge within 90 days for genes within the original clinical area. For more information and to request online, please visit www.invitae.com/re-requisition.

FAMILY VARIANT TESTING: Invitae offers Family Variant Testing at no additional charge within 90 days for the genes in which the original family member's variant was identified. In such cases, please use the Family Variant Testing/VUS Resolution requisition form (TRF920), available at www.invitae.com/forms.

PRELIMINARY-EVIDENCE GENES: Invitae's primary panels contain genes for which there is definitive evidence that variants in these genes cause specific diseases. Preliminary-evidence genes are genes for which there is only early evidence of a relationship between variants in these genes and specific diseases. All preliminary-evidence genes are indicated as such on the requisition form below.

ASSAY: Invitae is a CAP-accredited and CLIA-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS). Search for details on the analysis of any gene in our test catalog at www.invitae.com/physician/search.

Invitae continually updates its panels based on the most recent evidence. Please note that if an order is placed using an older version of these forms, Invitae reserves the right to upgrade any ordered panel(s) to the current version(s). To avoid confusion, please consider placing your order using our online test catalog.

To request a complimentary specimen collection kit visit www.invitae.com/request-a-kit

SHIPPING INSTRUCTIONS
Please ship specimen overnight in insulated containers:

Attn: Invitae Client Services
1400 16th Street
San Francisco, CA 94103
USA

STAT TURNAROUND TIME PANELS

SPECIAL INSTRUCTIONS: These panels have a guaranteed turnaround time of 5–12 calendar days from when the specimen is received. Genes cannot be removed and they cannot be ordered with any other non-STAT panels or genes. The option to re-requisition additional genes is available (see details above). Only blood and saliva are accepted (DNA is not accepted).

| Test code | Test name | # gene(s) | Gene list |
|-----------------------------|---|-----------|--|
| <input type="radio"/> 50001 | Invitae Breast Cancer STAT Panel | 7 | BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53 |
| | <input type="radio"/> 50001.1 Add-on ATM gene | 1 | ATM |
| | <input type="radio"/> 50001.2 Add-on CHEK2 gene | 1 | CHEK2 |
| <input type="radio"/> 50002 | Invitae BRCA1 and BRCA2 STAT Panel | 2 | BRCA1, BRCA2 |

FREQUENTLY ORDERED HEREDITARY CANCER PANELS

| | | | |
|-----------------------------|--|----|---|
| <input type="radio"/> 01102 | Invitae Common Hereditary Cancers Panel | 43 | APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, DICER1, EPCAM, GREM1, HOXB13, KIT, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PDGFRA, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, VHL |
| <input type="radio"/> 01101 | Invitae Multi-Cancer Panel | 80 | ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1 |
| <input type="radio"/> 01206 | Invitae Breast Cancer Guidelines-Based Panel | 11 | ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, TP53 |
| <input type="radio"/> 01204 | Invitae Breast and Gyn Cancers Guidelines-Based Panel | 19 | ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53 |
| <input type="radio"/> 01252 | Invitae Colorectal Cancer Guidelines-Based Panel | 12 | APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53 |
| | <input type="radio"/> 01252.1 Add-on guidelines genes with emerging data | 6 | BLM, CHEK2, GALNT12, GREM1, POLD1, POLE |
| <input type="radio"/> 01701 | Invitae Hereditary Breast and Ovarian Cancer Syndrome Panel | 2 | BRCA1, BRCA2 |
| <input type="radio"/> 01702 | Invitae Lynch Syndrome Panel | 5 | EPCAM, MLH1, MSH2, MSH6, PMS2 |

INDIVIDUAL GENES

| | | | | | | | | |
|------------------------------|------------------------------|-------------------------------|------------------------------|-----------------------------|------------------------------|------------------------------|-------------------------------|-----------------------------|
| <input type="radio"/> APC | <input type="radio"/> BRCA1 | <input type="radio"/> CHEK2 | <input type="radio"/> HOXB13 | <input type="radio"/> MSH6 | <input type="radio"/> PDGFRA | <input type="radio"/> PTEN | <input type="radio"/> SDHB | <input type="radio"/> STK11 |
| <input type="radio"/> ATM | <input type="radio"/> BRCA2 | <input type="radio"/> DICER1 | <input type="radio"/> KIT | <input type="radio"/> MUTYH | <input type="radio"/> PMS2 | <input type="radio"/> RAD50 | <input type="radio"/> SDHC | <input type="radio"/> TP53 |
| <input type="radio"/> AXIN2 | <input type="radio"/> BRIP1 | <input type="radio"/> EPCAM | <input type="radio"/> MEN1 | <input type="radio"/> NBN | <input type="radio"/> POLD1 | <input type="radio"/> RAD51C | <input type="radio"/> SDHD | <input type="radio"/> TSC1 |
| <input type="radio"/> BARD1 | <input type="radio"/> CDH1 | <input type="radio"/> GALNT12 | <input type="radio"/> MLH1 | <input type="radio"/> NF1 | <input type="radio"/> POLE | <input type="radio"/> RAD51D | <input type="radio"/> SMAD4 | <input type="radio"/> TSC2 |
| <input type="radio"/> BLM | <input type="radio"/> CDKN2A | <input type="radio"/> GREM1 | <input type="radio"/> MSH2 | <input type="radio"/> PALB2 | <input type="radio"/> POT1 | <input type="radio"/> SDHA | <input type="radio"/> SMARCA4 | <input type="radio"/> VHL |
| <input type="radio"/> BMPR1A | <input type="radio"/> CDK4 | | | | | | | |